Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
35.93
+0.12 (0.34%)
At close: Sep 28, 2026, 4:00 PM EDT
35.61
-0.32 (-0.89%)
Pre-market: Sep 29, 2026, 5:31 AM EDT
Castle Biosciences Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Castle Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $44. The average 1-year stock price forecast is 22.46% higher than the current stock price, while the lowest is $35 (-2.59%) and the highest is $57 (+58.64%).
Price Target: $44 (+22.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Castle Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 9 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Buy Maintains $40 → $50 | Buy | Maintains | $40 → $50 | +39.16% | Sep 22, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $40 | Buy | Maintains | $40 | +11.33% | Aug 3, 2026 |
| BTIG | BTIG | Buy Reiterates $40 → $44 | Buy | Reiterates | $40 → $44 | +22.46% | Aug 3, 2026 |
| Lake Street | Lake Street | Buy Maintains $52 → $57 | Buy | Maintains | $52 → $57 | +58.64% | Jul 31, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $43 → $36 | Buy | Maintains | $43 → $36 | +0.19% | Jul 31, 2026 |
Financial Forecast
Revenue This Year
373.17M
from 344.23M
Increased by 8.41%
Revenue Next Year
411.62M
from 373.17M
Increased by 10.30%
EPS This Year
-1.27
from -0.83
EPS Next Year
-0.94
from -1.27
EPS and Forward PE are based on non-GAAP adjusted numbers.